title: Fulminant HHV-8 associated Castleman's disease in a non-HIV, Kaposi sarcoma patient with borderline hemophagocytic syndrome.
authors.forename: Irena
authors.initials: I
authors.lastname: Barbarov
authors.forename: Maya
authors.initials: M
authors.lastname: Koren-Michowitz
authors.forename: Ginette
authors.initials: G
authors.lastname: Schiby
authors.forename: Orith
authors.initials: O
authors.lastname: Portnoy
authors.forename: David
authors.initials: D
authors.lastname: Livingstone
authors.forename: Gad
authors.initials: G
authors.lastname: Segal
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000008:administration & dosage; D005871:Castleman Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D018450:Disease Progression; D017809:Fatal Outcome; D015774:Ganciclovir / Q000008:administration & dosage; D005938:Glucocorticoids / Q000008:administration & dosage*; D019288:Herpesvirus 8, Human / Q000302:isolation & purification*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D017093:Liver Failure / Q000209:etiology; D008198:Lymph Nodes / Q000473:pathology*; D051359:Lymphohistiocytosis, Hemophagocytic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D051437:Renal Insufficiency / Q000209:etiology; D000069283:Rituximab; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology / Q000821:virology
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D005938:Glucocorticoids; D007155:Immunologic Factors; D000069283:Rituximab; D015774:Ganciclovir